Greg Friberg. Executive Vice President, Chief Research & Development Officer.

Greg Friberg Discusses Career Journey, What Brought Him to BioMarin

Our new Chief R&D Officer shares what drew him to medicine, how he found a home in biopharma and what about BioMarin’s science excites him the most.

Rebeca Costa standing in front of a banner at Carnival

Social Media Influencer Strives to Make Carnival Inclusive for All

Rebeca Costa is using her voice to help make Rio de Janeiro’s world-famous event more accessible.

PKU Advocate, Parent Shares Personal Experience with Early Diagnosis

This September for Newborn Screening Awareness Month, we spoke with Denise Queally, President of New England Connection for PKU and Allied Disorders, to learn more about why early diagnosis has been so meaningful for her family.

Breakthrough Science

We relentlessly pursue bold science to translate genetic discoveries into new medicines that advance the future of human health.

Learn More

Focus on Patients

We listen to and learn from patient communities to collaborate on solutions with the potential to help improve care.

Learn More

People-First Culture

Our talented and dedicated people represent the best the biotech industry has to offer and have helped shape a culture focused on working together to deliver for the patients we serve.

Learn More

BioMarin is a global biotechnology company with eight marketed products that treat life-threatening conditions.

Since our founding in 1997, we’ve applied our scientific expertise in understanding the underlying causes of genetic conditions to create transformative medicines, using a number of treatment modalities. Our approved medicines treat achondroplasia, severe hemophilia A and several rare inherited and lysosomal storage diseases. We’re also advancing an industry-leading pipeline of investigational medicines that are in various stages of clinical and preclinical development.

Learn More